Revenue growth has turned sharply negative, culminating in a 100% year-over-year decline by 2026Q1 as the company's sole royalty asset failed to provide meaningful top-line support.
Curis, Inc. (CRIS) annual income statement — 27-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 |
|---|
| Sales/Revenue | 4.31M | 9.44M | 10.91M | 10.02M | 10.16M | 10.65M | 10.84M | 10M | 10.43M | 9.9M | 7.53M | 7.88M | 9.84M | 15M | 16.97M | 14.76M | 16M | 8.59M | 8.37M | 16.39M | 14.94M | 6M | 4.95M | 11.05M | 18.39M | 1.09M | 997.08K | 3.21M |
| Revenue Growth % | -62.17% | -13.43% | 8.83% | -1.37% | -4.57% | -1.72% | 8.31% | -4.07% | 5.35% | 31.5% | -4.46% | -19.96% | -34.39% | -11.61% | 14.97% | -7.73% | 86.26% | 2.67% | -48.95% | 9.73% | 148.83% | 21.2% | -55.17% | -39.92% | 1592.64% | 8.97% | -68.96% | - |
| Cost of Goods Sold | 31K | 45K | 98K | 212K | 257K | 533K | 534K | 503K | 563K | 496K | 399K | 405.76K | 339.58K | 197.8K | 176.48K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.34B | 0 | -11.15M | 0 |
| COGS % of Revenue | - | 0.48% | 0.9% | 2.12% | 2.53% | 5.01% | 4.93% | 5.03% | 5.4% | 5.01% | 5.3% | 5.15% | 3.45% | 1.32% | 1.04% | - | - | - | - | - | - | - | - | - | 29019.19% | - | -1118.08% | - |
| Gross Profit | 4.28M | 9.4M | 10.81M | 9.81M | 9.9M | 10.12M | 10.3M | 9.5M | 9.87M | 9.4M | 7.13M | 7.47M | 9.5M | 14.8M | 16.8M | 14.76M | 16M | 8.59M | 8.37M | 16.39M | 14.94M | 6M | 4.95M | 11.05M | -5.32B | 1.09M | 12.15M | 3.21M |
| Gross Margin % | 99.28% | 99.52% | 99.1% | 97.88% | 97.47% | 94.99% | 95.07% | 94.97% | 94.6% | 94.99% | 94.7% | 94.85% | 96.55% | 98.68% | 98.96% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | -28919.19% | 100% | 1218.08% | 100% |
| Gross Profit Growth % | - | -13.06% | 10.18% | -0.95% | -2.09% | -1.8% | 8.42% | -3.69% | 4.92% | 31.9% | -4.61% | -21.37% | -35.8% | -11.86% | 13.77% | -7.73% | 86.26% | 2.67% | -48.95% | 9.73% | 148.83% | 21.2% | -55.17% | 100.21% | - | -91.05% | 278.14% | - |
| Operating Expenses | 40.24M | 42.34M | 55.35M | 58.14M | 62.92M | 52.18M | 35.2M | 33.86M | 39.2M | 59.16M | 47.18M | 39.61M | 25.37M | 24.22M | 25.92M | 21.97M | 21.64M | 18.63M | 21.49M | 24.76M | 24.99M | 21.87M | 20.58M | 20.96M | 94.29M | 73.26M | 54.53M | 17.09M |
| OpEx % of Revenue | - | 448.43% | 507.44% | 580.1% | 619.22% | 490.01% | 324.86% | 338.43% | 375.89% | 597.72% | 626.78% | 502.71% | 257.69% | 161.45% | 152.69% | 148.79% | 135.24% | 216.94% | 256.81% | 151.1% | 167.32% | 364.35% | 415.48% | 189.72% | 512.69% | 6742.87% | 5469.03% | 531.98% |
| Selling, General & Admin | 14.82M | 14.05M | 16.79M | 18.65M | 19.65M | 17.3M | 12.13M | 11.55M | 14.79M | 25.82M | 15.59M | 12.91M | 11.71M | 11.29M | 10.42M | 8.27M | 10.26M | 8.7M | 8.26M | 9.98M | 10.37M | 8.09M | 8.93M | 7.49M | 10.32M | 20.85M | 25.96M | 5.52M |
| SG&A % of Revenue | - | 148.75% | 153.92% | 186.04% | 193.35% | 162.43% | 111.96% | 115.5% | 141.78% | 260.84% | 207.09% | 163.82% | 118.93% | 75.28% | 61.41% | 56.04% | 64.15% | 101.31% | 98.72% | 60.92% | 69.46% | 134.77% | 180.36% | 67.75% | 56.11% | 1919.08% | 2603.45% | 171.99% |
| Research & Development | 25.42M | 28.25M | 38.56M | 39.5M | 43.28M | 34.88M | 23.07M | 22.3M | 24.41M | 33.34M | 31.59M | 26.7M | 13.66M | 12.93M | 15.49M | 13.69M | 11.37M | 9.93M | 13.23M | 14.78M | 14.59M | 13.71M | 11.57M | 13.4M | 14.06M | 29.07M | 17.42M | 10.43M |
| R&D % of Revenue | - | 299.21% | 353.52% | 394.05% | 425.87% | 327.58% | 212.9% | 222.93% | 234.11% | 336.88% | 419.69% | 338.89% | 138.77% | 86.17% | 91.28% | 92.75% | 71.08% | 115.63% | 158.09% | 90.18% | 97.68% | 228.32% | 233.61% | 121.28% | 76.44% | 2675.75% | 1747.5% | 324.88% |
| Other Operating Expenses | 0 | 45K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -104K | -1K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 27.05K | 75.07K | 75.07K | 75.08K | 69.91M | 23.34M | 11.15M | 1.13M |
| Operating Income | -35.95M | -32.9M | -44.54M | -48.33M | -53.02M | -42.06M | -24.9M | -24.36M | -29.33M | -49.76M | -58.04M | -56.48M | -15.86M | -9.42M | -18.62M | -7.2M | -5.64M | -10.04M | -13.12M | -8.37M | -10.05M | -15.87M | -15.62M | -9.91M | -79.39M | -72.17M | -42.39M | -13.87M |
| Operating Margin % | -833.4% | -348.43% | -408.34% | -482.21% | -521.75% | -395.01% | -229.79% | -243.46% | -281.29% | -502.73% | -771.08% | -716.91% | -161.14% | -62.77% | -109.71% | -48.79% | -35.24% | -116.94% | -156.81% | -51.1% | -67.32% | -264.35% | -315.48% | -89.72% | -431.67% | -6642.87% | -4250.95% | -431.98% |
| Operating Income Growth % | - | 26.13% | 7.84% | 8.84% | -26.04% | -68.95% | -2.23% | 16.97% | 41.05% | 14.26% | -2.76% | -256.07% | -68.45% | 49.43% | -158.52% | -27.76% | 43.87% | 23.44% | -56.66% | 16.71% | 36.63% | -1.55% | -57.63% | 87.51% | -9.99% | -70.28% | -205.49% | - |
| EBITDA | -35.86M | -32.73M | -44.34M | -48.08M | -52.79M | -41.91M | -24.75M | -24.23M | -29.16M | -49.52M | -57.85M | -56.32M | -15.71M | -9.27M | -18.49M | -7.1M | -4.95M | -9.29M | -12.12M | -7.07M | -8.62M | -14.85M | -14.55M | -8.41M | -76.96M | -45.55M | -31.24M | -12.89M |
| EBITDA Margin % | -831.22% | -346.64% | -406.48% | -479.67% | -519.45% | -393.53% | -228.46% | -242.21% | -279.59% | -500.35% | -768.51% | -714.87% | -159.57% | -61.82% | -108.96% | -48.06% | -30.95% | -108.19% | -144.87% | -43.15% | -57.72% | -247.44% | -293.76% | -76.13% | -418.46% | -4192.15% | -3132.87% | -401.17% |
| EBITDA Growth % | 5.11% | 26.18% | 7.78% | 8.92% | -25.96% | -69.29% | -2.16% | 16.89% | 41.13% | 14.38% | -2.71% | -258.56% | -69.35% | 49.85% | -160.65% | -43.3% | 46.72% | 23.33% | -71.38% | 17.96% | 41.96% | -2.09% | -72.97% | 89.07% | -68.96% | -45.81% | -142.43% | - |
| D&A (Non-Cash Add-back) | 94K | 169K | 203K | 255K | 233K | 158K | 144K | 125K | 177K | 235K | 193K | 160.81K | 155.08K | 141.52K | 126.54K | 107.4K | 686.5K | 751.21K | 998.6K | 1.3M | 1.43M | 1.01M | 1.08M | 1.5M | 2.43M | 26.63M | 11.15M | 989.49K |
| EBIT | -21.93M | -5.4M | -42.77M | -45.39M | -51.9M | -40.96M | -24.81M | -27.3M | -28.65M | -49.35M | -57.63M | -55.66M | -14.98M | -8.48M | -16.21M | -9.86M | -4.44M | -10.04M | -13.12M | -8.37M | -10.05M | -15.87M | -15.62M | -9.91M | -75.9M | -72.17M | -42.39M | -13.87M |
| Net Interest Income | 270K | -1.87M | 1.15M | 919K | -3.65M | -4.26M | -5.03M | -4.23M | -3.24M | -3.45M | -2.37M | -3.05M | -3.58M | -3.68M | -54.23K | 100.03K | 137.66K | 222.31K | 986.41K | 1.52M | 1.38M | 887.31K | 128.72K | -266.19K | 120.01K | 2.07M | 1.42M | 0 |
| Interest Income | 270K | 316K | 1.77M | 2.94M | 1.12M | 211K | 63K | 614K | 684K | 513K | 405K | 824.85K | 165.1K | 164.65K | 149.94K | 100.03K | 137.66K | 222.31K | 990.26K | 1.61M | 1.58M | 1.2M | 539.85K | 427.91K | 1.07M | 2.85M | 1.9M | 0 |
| Interest Expense | 0 | 2.19M | 615K | 2.02M | 4.77M | 4.47M | 5.09M | 4.85M | 3.93M | 3.97M | 2.78M | 3.33M | 3.75M | 3.84M | 204.17K | 0 | 0 | 0 | 3.85K | 84.84K | 196.2K | 308.42K | 411.14K | 694.1K | 946.87K | 783.8K | 481.31K | 0 |
| Other Income/Expense | 14.8M | 25.32M | 1.15M | 919K | -3.65M | -3.37M | -5.01M | -7.79M | -3.24M | -3.56M | -2.37M | -26.85M | -2.87M | -2.91M | -7.3M | -2.66M | 1.2M | 222.31K | 996.55K | 1.06M | 1.23M | 1.01M | 1.72M | 9.91M | 79.39M | -9.69M | -309.38M | 1.78K |
| Pretax Income | -21.15M | -7.58M | -43.39M | -47.41M | -56.67M | -45.44M | -29.91M | -32.14M | -32.58M | -53.32M | -60.41M | -58.98M | -18.73M | -12.32M | -16.42M | -9.86B | -4.44B | -9.82B | -12.12B | -6.96B | -8.83B | -14.86B | -13.9B | -11.62B | -82.32B | -81.86M | -351.77M | -13.87M |
| Pretax Margin % | -490.33% | -80.29% | -397.77% | -473.04% | -557.69% | -426.67% | -276.03% | -321.28% | -312.38% | -538.66% | -802.59% | -748.64% | -190.27% | -82.14% | -96.73% | -66783.01% | -27721.44% | -114350.05% | -144898.45% | -42494.55% | -59115.8% | -247485.31% | -280746.11% | -105204.62% | -447596.67% | -7534.6% | -35280.09% | -431.92% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.16M | 3.59M | 3.7M | 9.37M | 2.55M | -1.89M | -973.52K | -996.55K | -1.41M | -1.23M | -1.01M | -1.72M | 1.71M | 2.11M | 0 | 307.97M | -1.76M |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -5.36% | -19.19% | -30.03% | -57.1% | -0.03% | 0.04% | 0.01% | 0.01% | 0.02% | 0.01% | 0.01% | 0.01% | -0.01% | -0% | 0% | -87.55% | 12.72% |
| Net Income | -21.15M | -7.58M | -43.39M | -47.41M | -56.67M | -45.44M | -29.91M | -32.14M | -32.58M | -53.32M | -60.41M | -58.98M | -18.73M | -12.32M | -16.42M | -9.86M | -4.44M | -9.82M | -12.12M | -6.96M | -8.83M | -14.86M | -13.9M | -11.62M | -82.32M | -81.86M | -350.35M | -12.11M |
| Net Margin % | -490.33% | -80.29% | -397.77% | -473.04% | -557.69% | -426.67% | -276.03% | -321.28% | -312.38% | -538.66% | -802.59% | -748.64% | -190.27% | -82.14% | -96.73% | -66.78% | -27.72% | -114.35% | -144.9% | -42.49% | -59.12% | -247.49% | -280.75% | -105.2% | -447.6% | -7534.6% | -35137.73% | -377.03% |
| Net Income Growth % | 45.65% | 82.53% | 8.49% | 16.34% | -24.73% | -51.92% | 6.95% | 1.33% | 38.9% | 11.74% | -2.42% | -214.92% | -51.99% | 24.94% | -66.52% | -122.28% | 54.85% | 18.98% | -74.08% | 21.12% | 40.56% | -6.84% | -19.62% | 85.88% | -0.55% | 76.63% | -2793.12% | - |
| Net Income (Continuing) | -21.15M | -7.58M | -43.39M | -47.41M | -56.67M | -45.44M | -29.91M | -32.14M | -32.58M | -53.32M | -60.41M | -58.98M | -18.73M | -12.32M | -16.42M | -9.86M | -4.44M | -9.82M | -12.12M | -6.96M | -8.83M | -14.86M | -13.9M | -11.62M | -82.32M | -81.86M | -350.35M | -12.11M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -9.90 | -11.60 | -137.60 | -179.20 | -242.80 | -198.40 | -245.80 | -387.40 | -393.40 | -3575.20 | -900.00 | -960.00 | -440.00 | -300.00 | -420.00 | -260.00 | -120.00 | -300.00 | -380.00 | -260.00 | -360.00 | -620.00 | -660.00 | -33.00 | -257.00 | -5139.20 | -39601.20 | -2267.40 |
| EPS Growth % | 85.43% | 91.57% | 23.21% | 26.19% | -22.38% | 19.28% | 36.55% | 1.53% | 89% | -297.24% | 6.25% | -118.18% | -46.67% | 28.57% | -61.54% | -116.67% | 60% | 21.05% | -46.15% | 27.78% | 41.94% | 6.06% | -1900% | 87.16% | 95% | 87.02% | -1646.55% | - |
| EPS (Basic) | - | -11.60 | -137.60 | -179.20 | -242.80 | -198.40 | -245.80 | -387.40 | -393.40 | -3575.20 | -900.00 | -960.00 | -440.00 | -300.00 | -420.00 | -260.00 | -120.00 | -300.00 | -380.00 | -260.00 | -360.00 | -620.00 | -660.00 | -33.00 | -257.00 | -5139.20 | -39601.20 | -2267.40 |
| Diluted Shares Outstanding | 2.14M | 658.2K | 315.31K | 264.66K | 233.48K | 228.92K | 121.67K | 82.95K | 82.8K | 14.91K | 66.39K | 61.68K | 42.99K | 41.17K | 39.53K | 38.17K | 37.48K | 32.53K | 31.69K | 27.46K | 24.53K | 24.04K | 21.34K | 18.01K | 16.13K | 15.93K | 8.85K | 5.34K |
| Basic Shares Outstanding | 2.14M | 658.2K | 315.31K | 264.66K | 233.48K | 228.92K | 121.67K | 82.95K | 82.8K | 14.91K | 66.39K | 61.68K | 42.99K | 41.17K | 39.53K | 38.17K | 37.48K | 32.53K | 31.69K | 27.46K | 24.53K | 24.04K | 21.34K | 18.01K | 16.13K | 15.93K | 8.85K | 5.34K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying CRIS stock.
For fiscal year 2025, Curis, Inc. (CRIS) reported total revenue of $9.4M. This represents a 194.0% increase compared to $3.2M in 1999.
Curis, Inc. (CRIS) reported a net loss of $7.6M for the fiscal year ending 2025.
Curis, Inc. (CRIS) reported an operating income of $-32.9M, resulting in an operating profit margin of -348.4%. This margin reflects the operational efficiency of the business before interest and taxes.
Curis, Inc. (CRIS) generated $9.4M in gross profit for the year, representing a gross profit margin of 99.5%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Imminent liquidity exhaustion
Metrics are mathematically derived from official filings.
Royalty Revenue Facing Structural Decline
As reported in recent financial filings, Curis experienced a sharp revenue contraction, culminating in a total loss of quarterly revenue by 2026Q1, which highlights the fragility of a business model entirely dependent on the declining royalty stream from a single legacy asset, Erivedge.
The company's revenue trajectory has shifted from modest volatility to a complete cessation of reported inflows, suggesting that the underlying royalty agreement may no longer provide a meaningful buffer. Investors should monitor whether this reflects a permanent loss of commercial relevance for the licensed asset or merely a temporary reporting anomaly.
R&D Intensity Outpacing Financial Capacity
Based on the provided income statement data, Curis maintains a high-fixed cost structure where R&D expenditures consistently dwarf passive royalty income, creating a persistent structural deficit that appears to have accelerated the depletion of the company's limited cash reserves over the last ten quarters.
The firm's inability to scale back clinical trial spending in alignment with declining revenues suggests a lack of operational flexibility. This cost structure implies that the company is effectively trading its remaining liquidity for the theoretical optionality of its pipeline, a strategy that appears increasingly unsustainable.
Operating Leverage Constrained by Burn
According to historical income statements, Curis exhibits a severe lack of operating leverage, as the company has failed to demonstrate any meaningful reduction in SG&A or R&D costs even as revenue growth turned negative, leading to consistently deep operating losses across all observed periods.
The absence of a scalable cost base indicates that the company remains in a high-risk development phase where every dollar of revenue is insufficient to cover the overhead of its clinical programs. This suggests that the firm is highly sensitive to capital market conditions, as it lacks the internal cash generation to fund its own operations.
Liquidity Crisis Threatens Pipeline Viability
As indicated by the most recent quarterly data, the company's cash position has reached a critical threshold, raising significant concerns regarding its ability to continue as a going concern without immediate and potentially highly dilutive financing to support its ongoing clinical development efforts.
While the market may focus on the potential of the emavusertib program, the financial reality suggests that the company may be forced to prioritize survival over clinical progress. Investors should consider the high probability that current shareholders will face substantial dilution if the company attempts to bridge its funding gap through equity issuance.